BMS signs deal with Concerto HealthAI
The partnership will give the American pharma giant access to Concerto’s eurekaHealth AI insights platform.
Read More
Tag: cancer drug development
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
